Exercise to prevent osteoporosis in breast cancer survivors.

Not Applicable

Recruiting

• Conditions: Osteoporosis; Breast Cancer; Musculoskeletal - Osteoporosis; Cancer - Breast

• Registration Number: ACTRN12608000220369
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-04-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Women will be included if they : Are postmenopausal, based on age, menses history, and/or surgery. Have stage I-III breast cancer. Have oestrogen receptor and/or progesterone receptor positive breast cancer. Have commenced taking aromatase inhibitor within 10 weeks. Have Eastern Collaborative Oncology Group performance status <=2 (Oken et al, 1982). Are sedentary.

Exclusion Criteria

Women will be excluded if they have:
Any clinical or radiological evidence of distant spread of disease.
Taken any HRT within the past 12 months.
Taken bisphosphonates within the past 6 months.
Received prior treatment with continuous systemic glucocorticoids within the past 6 months.
Current treatments with any drugs known to affect the skeleton (eg Calcitonin, calcitrol, mithramycin or gallium nitrate).
A history of diseases that influence bone metabolism, such as Paget's disease or ongoing thyroid toxicosis.
Previous or concomitant malignancy (apart from breast cancer) within the past 5 years except adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bone Mineral Density: DEXA scans of spine and hip[baseline, 6 months, 12 months]

Secondary Outcome Measures

Name	Time	Method
Biochemical markers of bone remodelling (bone formation and resorption): automated imunoassay[baseline, 6 months, 12 months];Self report outcomes: quality of life questionnaire and medical outcomes survey short forms[baseline, 6 months, 12 months];Lymphoedema status: Bioimpedance spectroscopy[baseline, 6 months, 12 months];Bone Mineral Density (BMD): DEXA scans of trochanteric, femoral neck and spinal BMD[baseline, 6 months, 12 months]